Keyphrases
COVID-19
100%
Randomized Controlled Trial
47%
Hospitalized Patients
32%
Neutralizing Monoclonal Antibody
30%
Placebo
30%
Clinical Trials
30%
Patients with COVID-19
28%
Standard of Care
25%
Randomized Trial
19%
Q-learning
18%
Randomized Clinical Trial
18%
Metformin
18%
Hazard Ratio
17%
Confidence Interval
16%
Placebo Groups
16%
Coronavirus Disease (COVID)
16%
COVID-19 Treatment
16%
Out-of-hospital Cardiac Arrest
15%
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO)
15%
Simulation Study
15%
Network Meta-analysis
14%
Commensurate Prior
13%
Therapeutic Monoclonal Antibody
13%
Utility-based
13%
Randomized Comparative Trial
13%
Disease Progression
13%
Semi-parametric
13%
Losartan
13%
Randomized Methods
13%
Adaptive Randomization
13%
Immunological Biomarkers
13%
Nonexchangeable
13%
Phase I Clinical Trial
13%
Device Surveillance
13%
Spinal Cord Stimulation
13%
Borrowing Strength
13%
Type I Error Rate
12%
Model Misspecification
12%
Nucleocapsid Antigen
12%
Resuscitation
11%
Treatment Effect
11%
Cardiopulmonary Resuscitation
11%
Fluvoxamine
11%
Ivermectin
11%
Odds Ratio
11%
Sustained Recovery
10%
Moderate Exercise
10%
Clinical Outcomes
10%
Unvaccinated
10%
Cancer Data
10%
Medicine and Dentistry
COVID-19
65%
Severe Acute Respiratory Syndrome Coronavirus 2
35%
Clinical Trial
30%
Glycon
26%
Placebo
23%
Randomized Controlled Trial
20%
Resuscitation
20%
Ivermectin
13%
Fluvoxamine
13%
Outpatient
12%
Intention-to-Treat Analysis
11%
Odds Ratio
11%
Body Mass Index
11%
Ventricular Fibrillation
9%
Out of Hospital Cardiac Arrest
9%
Arm
9%
Infection
9%
Drug Therapy
8%
Extracorporeal Membrane Oxygenation
8%
Antivirus Agent
7%
Hazard Ratio
7%
Heart Arrest
7%
Left Ventricular Assist Device
6%
Heart Right Ventricle Failure
6%
Controlled Clinical Trial
6%
Spinal Cord Stimulation
6%
Cohort Analysis
6%
Heart Transplantation
6%
Sodium Nitroprusside
6%
Mobile Health
6%
Myelodysplastic Syndrome
6%
Immunoglobulin
6%
Neuromodulation
6%
Virus Nucleocapsid
6%
Atherosclerosis
6%
Hyperimmune Globulin
6%
Congestive Heart Failure
6%
Prospective Cohort Study
6%
Biological Marker
6%
Triage
6%
Injury
6%
Health Care Cost
6%
Health System
6%
Electronic Health Record
5%
Adverse Event
5%